Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 7.45 7.30 7.60 7.45 7.45 7.45 66,656 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.1 -2.7 - 10

Evgen Pharma Share Discussion Threads

Showing 1601 to 1625 of 1850 messages
Chat Pages: 74  73  72  71  70  69  68  67  66  65  64  63  Older
DateSubjectAuthorDiscuss
26/9/2019
08:06
So what your saying is, the company have been collecting data without knowing what data they are collecting.. hmmmm well how would they know they have collected the right data in the first place?
90005nelson
26/9/2019
07:15
Morning Nelson,thanks I was specifically referring to risks associated with the SAH trials, as it seems you feel there aren't many/any? Evgen have no idea what the data results are for these Secondary endpoints - and will only know when all results collated and analysed independently. That's the nature of double-blind trials. So, what I'm saying is that your thoughts about somehow they know how the secondary endpoints isn't correct. And there-in lies the risk.
pennyfalls
25/9/2019
12:08
To understand the risk you need to know what the future plans EVG are: Big pharma companies are very interested in SFX-01 and one even tried to buy Evgen shortly before it was floated back in December 2015.But Franklin and his team want to deliver Phase II data on both breast cancer and SAH before concluding a licensing deal or dealsThere's no guarantee of concluding any deal or deals. EVG can be bought for less than £40M.
90005nelson
25/9/2019
08:24
Thanks Nelson.. so let me ask you a direct question relating to what you appear to be saying: What is the risk here?
pennyfalls
24/9/2019
21:16
"Following discussions with our clinicians and statistical advisers, we have decided to unblind the SAS trial's primary and secondary endpoint data at the same time. By doing this, we will fully maintain the blinded integrity of the secondary endpoint data, which in this trial are particularly important as they will form the basis of the primary endpoints in subsequent studies. This approach will maximise the commercial value of the dataset from the SAS trial."This was taken from the RNS 18th March 2019. At that time, all the primary endpoint information was in that dataset along with 27 months worth of secondary endpoint information.
90005nelson
24/9/2019
20:36
So the last participant was February 2019 and they had taken the last data in September 2019, several months later, how much secondary endpoint information was in the database by March 2019 (when they made the decision to maximize commercial value of database) bearing in mind, they would have started collecting the above data from December 2016.
90005nelson
24/9/2019
20:23
Hi Nelson, I'm not saying it won't be. I'm testing out opinions. I don't need clinical data or literature to back up concerns! Concerns are born of experience and being circumspect, and pure common sense. If there was literature to back up concerns for all fledgling drugs then there would be no trials at all ! THIS trial WILL provide the literature, with little existing antecedence. The trials themselves and endpoints will , in themselves, be the future references for what you suggest! What you're saying, in essence, is that there is no risk based on little evidence.. And that's risky.
pennyfalls
24/9/2019
20:11
"SFX-01 works by activating the Nrf2 pathway which in turn activates the expression of genes that promote the body's innate capacity to control the oxidative stress and inflammation that underpin many chronic diseases." There's plenty of literature and compelling preclinical evidence to support Sulforaphane/ SFX-01, but can you provide any literature to back up your concerns that SFX-01 won't be an ideal candidate for treatment of patients with SAH?
90005nelson
24/9/2019
19:36
Hi Nelson - thanks for that But if the secondary endpoints (cognitive improvements - "among others") aren't sufficiently statistically significant, where would that leave us? Would that leave us with a drug that is safe, has some blood flow advantages, but still leaves people cognitively impaired? And is that of use commercially?
pennyfalls
24/9/2019
18:41
So the first participant was in May 2016 and the last participant was February 2019. They decided in March 2019, for commercial purposes not to release the primary endpoint data until releasing the secondary endpoint data at the same time. How much primary endpoint information would they have on their database by March 2019.? "We are excited by the outcome of this blinded study in an indication where there has been no significant clinical advance in more than 20 years," added Clare."
90005nelson
24/9/2019
17:30
Nelson - How can you say "SAH results nothing to worry about there"? The primary and secondary endpoints are to be announced together, and there would be no Market anticipation if everything was all in the bag already. We are still awaiting results ! (with a slight caveat that they've stated rather cryptically that this is for "commercial considerations". This could be seen as a teaser for all going well - or just more food for confirmation bias) and Nobby..thanks again.. and Timbo...are you there?
pennyfalls
24/9/2019
14:44
All the information I give out stems from their RNS announcements. Feel free to research them yourself
90005nelson
24/9/2019
14:40
>> pf Sulforaphane hits multiple targets. You can't switch that on and off so all the targets are being affected all the time. The question is whether that is a good thing in all indications. I think it is the scientist in me that wants a drug which is clean in terms of it's therapeutic effects, although I stress the multiple effects may well not be an issue and may in fact be a benefit. So it could be my own prejudice hard wired into me over many years being a scientist in the Pharma industry. So just IMHO and DYOR. In fact I would be interested in timbo's opinion as a fellow Pharma retiree and EVG investor.
nobbygnome
24/9/2019
14:33
load up at 13/14p rinse and repeat. more please...glh
purple11
24/9/2019
14:29
Hi 90005Nelson, Could you let me know if an interim analysis was performed on the first 90 SAH patients, and do you know whether the results for these patients showed a +ve trend?
diamondstar1
24/9/2019
13:34
SAH results, nothing to worry about there. They had a database from 90 participants over 34mnths before deciding to withhold primary endpoint results for commercial purposes.
90005nelson
24/9/2019
12:09
EVG are looking to attract a partner /co-investor and are possibly in communication with several potential's. It could well out license SFX-01 to more than one.
90005nelson
24/9/2019
11:40
Ps..Like it that people are airing a few honest views. Very healthy.
pennyfalls
24/9/2019
11:03
Indeed ASAT91 - and that had crossed my mind too - although if that was the plan, it had a very limited effect. But, I too , wondered whether a negative RNS was to shortly follow that - although, it was a legitimate update post-trial. Maybe I’ve just become far too cynical with the passing years( and experience of AIM !!) Nobby you said: “ When I asked that question at the research day last year that was effectively the answer I got. But it still nags away at the back of my mind that this could be an issue.” Could you elaborate on why this part nags away at you please and why it could be an issue? Much appreciated and sorry I roped you in...but this is VERY helpful to making a considered judgment.
pennyfalls
24/9/2019
09:09
Well I was about to share similar concerns so don't regret sharing too much. The overly positive tone of the most recent RNS releases about breast cancer results are what indicate to me that they are worried about the SAH results and trying to avoid a significant share price drop. I mean why are they even releasing an RNS on the breast cancer results! The results came out a while back, and there's nothing new in these releases that requires sharing with shareholders. So why upload it at all? The timing seems very coincidental 1/2 months before SAH results.
asat91
24/9/2019
08:40
>> pennyfalls I have replied to your PM. Don’t read too much into my nervousness. I have no expertise in the SAH area so my view is not based on direct experience. My overall concern about sulforaphane could be seen as a positive as well as a negative. As has been well documented in the literature it hits multiple targets in different pathways. Now you can’t turn those on and off so those inhibitions are going on all the time. The positive side to this is that these are all inhibitory/anti inflammatory effects and so perhaps that is beneficial. When I asked that question at the research day last year that was effectively the answer I got. But it still nags away at the back of my mind that this could be an issue. Once a scientist always a scientist and as usual I am probably over analysing the situation. Anyway I haven’t ruled out buying more so you need to keep that in mind too! I am beginning to regret unloading my thoughts; I should have just stuck to being a mad bull!
nobbygnome
24/9/2019
08:25
LWHT - great :o) NobbyGnome.. Can I just ask whether your gut feeling is based more on the company per se, the area of trial, or just the overall failure rate of Phase Trials? Have you had any experience of stroke/brain bleed developments professionally? If the endpoint in this trial is blood flow, and that’s an easier target, won’t the mortality rate data be for another later trial / data (pardon my ignorance) However - isn’t the idea not just to reduce mortality, but to also improve cognitition post-bleed in survivors - and if vasorestriction (up to 70% thereabouts ) is the cause of impairment, isn’t increased blood flow a legitimate endpoint to aim for?? And reading between the lines, haven’t they had some “surprising221; unexpected results - to be revealed -in the mental health area (cognition?), so maybe a sign - or am I conflating two things. Must admit to being a little spooked by the continuing sells each day, but also mindful of potential games/ and /or nervous PIs, as this usually happens before a rise OR fall. Take your pick.
pennyfalls
24/9/2019
07:36
Thanks for your further thoughts and kind comments Pennyfalls - and I may also take your advice on the name change too if I get a chance (for this, read overcome lazyness!) It is also interesting reading Nobby's take - like you I agree he is clearly a very knowledgeable person, especially when it comes to this niche area - but I really hope his gut feeling is wrong, as his reasoning is thought-provoking and approaches an angle that I had not even considered. Either way, we shall see.
lovewinshatelosses
23/9/2019
22:24
FAO NobbyGnome...I’;ve sent you a Private Message
pennyfalls
23/9/2019
22:17
Hi Personal troll ! Gone down all my messages ticking down..weeeirdo !
pennyfalls
Chat Pages: 74  73  72  71  70  69  68  67  66  65  64  63  Older
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191215 12:27:01